Ranexa Target Population Is 10%-25% Of Angina Patients; Sampling Will Be Key
CV Therapeutics' launch of its second-line angina product Ranexa (ranolazine) will include an aggressive sampling program
You may also be interested in...
CV Therapeutics is looking at Schering-Plough's Imdur (isosorbide) as a market "benchmark" for its Phase III anti-angina agent ranolazine.
Quintiles' contract sales division Innovex would receive up to one-third of the first two years of sales from a chronic stable angina treatment being developed by CV Therapeutics, under a commercialization deal announced May 11.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011